Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 14;6(6):CD008981.
doi: 10.1002/14651858.CD008981.pub3.

Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth

Debby P Utama  1 , Caroline A Crowther
Affiliations

Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth

Debby P Utama et al. Cochrane Database Syst Rev. .

Abstract

Background: Despite major advances in medical technology, the incidence of preterm birth remains high. The use of antenatal corticosteroid administered transplacentally, by intramuscular injection to women at risk of preterm birth, has reduced the incidence of respiratory distress syndrome and increased the survival rates of preterm infants. However, this intervention also comes with its own risks and side effects. Animal studies and early studies in pregnant women at risk of preterm birth have reported the use of an alternative route of administration, by direct intramuscular injection of corticosteroid into the fetus under ultrasound guidance, in an attempt to minimise the side-effect profile. Direct fetal corticosteroid administration may have benefits over maternal administration in terms of safety and efficacy.

Objectives: To assess if different routes of corticosteroid administration (maternal versus direct fetal) have effects on health outcomes for women and their babies.

Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (25 October 2017), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (25 October 2017) and reference lists of retrieved studies.

Selection criteria: Randomised controlled trials comparing maternal with direct fetal routes of antenatal corticosteroid administration in women at risk of preterm birth.

Data collection and analysis: The two review authors independently assessed study eligibility. In future updates of this review, at least two review authors will extract data and assess the risks of bias in included studies. We will also assess the quality of the evidence using the GRADE approach.

Main results: We did not identify any eligible randomised controlled trials to include in this review.

Authors' conclusions: The available clinical studies carried out so far on animals and human have shown that direct intramuscular injection of corticosteroid into the fetus under ultrasound guidance is feasible, but data on health outcomes are lacking. Uncertainty therefore persists as to which method could provide better efficacy and safety. Randomised controlled trials are required focusing on the benefits and harms of transplacental versus direct fetal corticosteroid treatment. Until the uncertainties have been addressed, it is advisable to stay with the current standard of antenatal transplacental maternally-administered corticosteroid treatment.

PubMed Disclaimer

Conflict of interest statement

Debby P Utama: none known.

Caroline A Crowther: none known.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies excluded from this review

Babovic 2015 {published data only}
    1. Babovic I, Radojicic Z, Plesinac S, Kastratovic Kotlica B, Sparic R. Direct intramuscular fetal or maternal antenatal corticosteroid therapy: short‐time effects on fetal behavior and oxygenation: a comparative study. Journal of Maternal‐fetal & Neonatal Medicine 2016; Vol. 29, issue 19:3213‐7. - PubMed

References to studies awaiting assessment

Ljubic 2000 {published data only}
    1. Ljubic A, Cvetkovic M, Sulovic V, Dukanac J, Antonovic O, Petkovic S. RDS prevention: direct fetal versus transplacental corticosteroid therapy [abstract]. XVI FIGO World Congress of Obstetrics & Gynecology (Book 2); 2000 Sept 3‐8; Washington DC, USA. 2000:156.

Additional references

AIHW 2015
    1. Australian Institute of Health and Welfare (AIHW). Australia's Mothers and Babies 2013—in brief. Perinatal statistics series no. 31. Cat. no. PER 72. Canberra: AIHW, 2015.
Antenatal Corticosteroid Guidelines Panel 2015
    1. Antenatal Corticosteroid Clinical Practice Guidelines Panel. Antenatal Corticosteroids Given to Women Prior to Birth to Improve Fetal, Infant, Child and Adult Health: Clinical Practice Guidelines 2015. The University of Auckland, Auckland. New Zealand.: Liggins Institute, 2015.
Babovic 2009
    1. Babovic I, Plesinak S, Opalik J, Devrnjaa V, Pavlovic I, Radojicic Z, et al. Intramuscular fetal corticosteroid therapy: short term effects on the fetus. Fetal Diagnosis and Therapy 2009;25(1):98‐101. - PubMed
Ballard 1995
    1. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. American Journal of Obstetrics and Gynecology 1995;173(1):254‐62. - PubMed
Beck 2010
    1. Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bulletin of the World Health Organization 2010;88(1):31‐8. - PMC - PubMed
Benediktsson 1993
    1. Benediktsson R, Lindsay RS, Noble J, Secki JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341(8841):339‐41. - PubMed
Brownfoot 2013
    1. Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006764.pub3] - DOI - PubMed
Crowther 2015
    1. Crowther CA, McKinlay CJD, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] - DOI - PMC - PubMed
Dalziel 2005
    1. Dalziel SR, Lim VK, Lambert A, McCarthy D, Parag V, Rodgers A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trials. BMJ 2005;331(7518):665. - PMC - PubMed
Doyle 2001
    1. Doyle LW, Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks gestation: refining the prognosis. Pediatrics 2001;108(1):134‐41. - PubMed
Evans 1993
    1. Evans MI, Pryde PG, Reichler A, Bardicef M, Johnson MP. Fetal drug therapy. Western Journal of Medicine 1993;159(3):325‐32. - PMC - PubMed
Fowden 1996
    1. Fowden AL, Szemere J, Hughes RS, Forhead AJ. The effects of cortisol on the growth rate of the sheep fetus during late gestation. Journal of Endocrinology 1996;151(1):97‐105. - PubMed
Goldenberg 2007
    1. Goldenberg R, Culhane JF, Iams J, Romero R. Epidemiology and causes of preterm birth. Lancet 2007;371(9606):73‐82. - PMC - PubMed
Gordon 2002
    1. Gordon MC, Narula K, O'Shaughnessy R, Barth WH Jr. Complications of third trimester amniocentesis using continuous ultrasound guidance. Obstetrics & Gynecology 2002;99(2):255‐9. - PubMed
Haram 2003
    1. Haram K, Mortensen JH, Wollen AL. Preterm delivery: an overview. Acta Obstetricia et Gynecologica Scandinavica 2003;82(8):687‐704. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jackson 2003
    1. Jackson JR, Kleeman S, Doerzbacher M, Lambers DS. The effect of glucocorticosteroid administration on fetal movements and biophysical profile scores in normal pregnancies. Journal of Maternal‐fetal & Neonatal Medicine 2003;13(1):50‐3. - PubMed
Jobe 1993
    1. Jobe AH, Polk D, Ikegami M, Newnham J, Sly P, Kohen R, et al. Lung responses to ultrasound‐guided fetal treatments with corticosteroids in preterm lambs. Journal of Applied Physiology 1993;75(5):2099‐105. - PubMed
Jobe 1998
    1. Jobe AH, Newnham J, Willet K, Sly P, Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics 1998;102(5):1116‐25. - PubMed
Jobe 2004
    1. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. American Journal of Obstetrics and Gynecology 2004;190(4):878‐81. - PubMed
Liggins 1972
    1. Liggins GC, Howie RNA. A control trial of antepartum glucocorticoid treatment in prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50(4):515‐25. - PubMed
Ljubic 1999
    1. Ljubic A, Cvetkovic M, Sulovic V, Radunovic N, Antonovic O, Vukolic D, et al. New technique for artificial lung maturation. Direct intramuscular fetal corticosteroid therapy. Clinical and Experimental Obstetrics and Gynecology 1999;26(1):16‐9. - PubMed
McGoldrick 2016
    1. McGoldrick E, Brown J, Middleton P, McKinlay CJD, Haas DM, Crowther CA. Antenatal corticosteroids for fetal lung maturation: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD012156] - DOI
Moss 2003
    1. Moss TJ, Doherty DA, Nitsos I, Harding R, Newnham JP. Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. American Journal of Obstetrics and Gynecology 2003;189(6):1751‐7. - PubMed
Newnham 1999
    1. Newnham JP, Evans SF, Godfrey ME, Huang WL, Ikegami M, Jobe A. Maternal, but not fetal, administration of corticosteroids restricts fetal growth. Journal of Maternal‐Fetal Medicine 1999;8(3):81‐7. - PubMed
NIH 1995
    1. Anonymous. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA 1995;273(5):413‐8. - PubMed
RCOG 2010
    1. Royal College of Obstetricians and Gynaecologists. Amniocentesis and Chorionic Villus Sampling Green‐top Guideline 8. London: RCOG, June 2010. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts 2017
    1. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD004454.pub3] - DOI - PMC - PubMed
Saigal 2007
    1. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2007;371(9608):261‐9. - PubMed
WHO 2015
    1. World Health Organization. WHO Recommendations on Interventions to Improve Preterm Birth Outcomes. Geneva: World Health Organization, 2015. - PubMed

References to other published versions of this review

Utama 2011a
    1. Utama DP, Crowther CA. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008981] - DOI - PubMed
Utama 2011b
    1. Utama DP, Crowther CA. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD008981.pub2] - DOI - PubMed

Publication types

Substances

LinkOut - more resources